+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sirolimus"

From
Organ Transplant Immunosuppressant Drugs Market Report 2025 - Product Thumbnail Image

Organ Transplant Immunosuppressant Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Immunosuppressants Market Report 2025 - Product Thumbnail Image

Immunosuppressants Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Immunomodulator Market Report 2025 - Product Thumbnail Image

Immunomodulator Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Treatment Market Report 2025 - Product Thumbnail Image

Graft Versus Host Disease (GVHD) Treatment Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
Acute Graft-Versus-Host Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Graft-Versus-Host Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • June 2024
  • 80 Pages
  • Global
From
From
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Sirolimus, also known as rapamycin, is an immunosuppressive drug used to prevent organ rejection in transplant patients. It works by inhibiting the activity of T-cells, which are responsible for attacking foreign bodies. Sirolimus is also used to treat certain types of cancer, such as lymphoma and Kaposi's sarcoma. It is often used in combination with other immunosuppressive drugs, such as cyclosporine and tacrolimus. Sirolimus is available in both oral and intravenous formulations. It is generally well-tolerated, with the most common side effects being nausea, vomiting, and diarrhea. It is also associated with an increased risk of infection and certain types of cancer. The sirolimus market is highly competitive, with several major players. These include Pfizer, Novartis, Merck, and Astellas. Other companies, such as Mylan and Teva, also offer generic versions of the drug. Show Less Read more